亚太地区罕见疾病基因检测市场：分析与预测（2023-2033）

2023年亚太罕见疾病基因检测市值达5.8亿美元。

预计到 2033 年，市场规模将达到 24 亿美元，2023-2033 年预测期间复合年增长率为 15.25%。全基因测序(WGS) 和全EXOME定序(WES) 等先进技术分别分析个体的整个遗传密码（基因组）或特定的蛋白质转录区（EXOME）。这些技术有助于检测与罕见疾病相关的遗传变异、突变和异常。

受多种因素影响，亚太地区罕见疾病基因检测市场正经历显着成长。意识的提高、基因检测技术的进步以及医疗成本的上升都有助于市场的扩张。此外，该地区庞大的人口和多样化的基因谱为基因检测提供者提供了巨大的机会。旨在改善医疗基础设施和扩大基因检测服务范围的政府措施将进一步推动市场成长。此外，医疗机构、研究机构和行业相关人员之间的合作正在促进针对该地区独特需求的创新基因检测解决方案的开发和实施。随着对精准医疗和个人化医疗保健的日益关注，亚太地区罕见疾病基因检测市场预计在可预见的未来将持续扩张和创新。

本报告研究了亚太地区罕见疾病基因检测市场，并提供了市场概况，包括按疾病类型、技术、国家和参与市场的公司概况分類的趋势。

目录

执行摘要

第一章 市场

• 市场展望
• 产业分析
• 市场动态
  • 概述
  • 市场驱动力
  • 市场挑战
  • 市场机会

第二章 罕见疾病基因检测市场（分地区）

• 亚太罕见疾病基因检测市场
  • 市场动态
  • 市场规模及预测

第三章 公司简介

The Asia Pacific Rare Disease Genetic Testing Market Expected to Reach $2.40 Billion by 2033

Introduction to Asia-Pacific Rare Disease Genetic Testing Market

The Asia-Pacific rare disease genetic testing market was valued at $0.58 billion in 2023 and is anticipated to reach $2.40 billion by 2033, witnessing a CAGR of 15.25% during the forecast period 2023-2033. Advanced technologies like whole-genome sequencing (WGS) and whole-exome sequencing (WES) analyze an individual's entire genetic code (genome) or specific protein-coding regions (exome), respectively. They aid in detecting genetic variations, mutations, or abnormalities linked to rare diseases.

Market Introduction

The Asia-Pacific (APAC) rare disease genetic testing market is witnessing notable growth driven by various factors. Increased awareness, advancements in genetic testing technologies, and rising healthcare expenditure contribute to market expansion. Moreover, the region's large population base and diverse genetic profiles present significant opportunities for genetic testing providers. Government initiatives aimed at improving healthcare infrastructure and expanding access to genetic testing services further propel market growth. Additionally, collaborations between healthcare organizations, research institutions, and industry players facilitate the development and adoption of innovative genetic testing solutions tailored to the region's specific needs. With a growing focus on precision medicine and personalized healthcare, the APAC rare disease genetic testing market is poised for continued expansion and innovation in the foreseeable future.

Market Segmentation:

Segmentation 1: by Disease Type

• Gastroenterology Disease
• Endocrine and Metabolism Disease
• Cardiovascular Disease
• Neurology Disease
• Hematology and Oncology Disease
• Dermatology Disease
• Other Diseases

Segmentation 2: by Technology

• Sanger Sequencing
• PCR
• NGS
• Microarrays
• Others (Targeted Cytogenetics, Karyotyping, and FISH)

Segmentation 3: by Country

• Japan
• India
• China
• South Korea
• Australia
• Singapore
• Rest-of-Asia-Pacific

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The APAC rare disease genetic testing market has been extensively segmented based on various categories, such as disease type, technology, and country. This can help readers understand which segments account for the largest share and which are well-positioned to grow in the coming years.

Competitive Strategy: The APAC rare disease genetic testing market has numerous established players paving their way into providing tests, panels, and assays in the market. Key players in the global rare disease genetic testing market analyzed and profiled in the study involve established players offering various disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Some of the prominent names established in this market are:

• 3billion, Inc.
• Konica Minolta (Ambry Genetics, Inc.)
• BGI Group
• Strand Life Science Pvt Ltd.

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1 Market

• 1.1 Market Outlook
  • 1.1.1 Product Definition
  • 1.1.2 Inclusion and Exclusion Criteria
    • 1.1.2.1 Inclusion Criteria
    • 1.1.2.2 Exclusion Criteria
  • 1.1.3 Market Overview
    • 1.1.3.1 Market Footprint
    • 1.1.3.2 Market Size and Future Growth Potential
  • 1.1.4 COVID-19 Impact on the Market
    • 1.1.4.1 Impact on Research and Clinical Operations
    • 1.1.4.2 COVID-19 Impact: Current Scenario of the Market
• 1.2 Industry Analysis
  • 1.2.1 Regulatory Framework
    • 1.2.1.1 Legal Requirements and Framework in Asia-Pacific
      • 1.2.1.1.1 Japan
      • 1.2.1.1.2 China
      • 1.2.1.1.3 India
      • 1.2.1.1.4 Taiwan
  • 1.2.2 Patent Analysis
    • 1.2.2.1 Patent Filing Trend (by Country)
    • 1.2.2.2 Patent Filing Trend (by Year)
  • 1.2.3 Funding Scenario
• 1.3 Market Dynamics
  • 1.3.1 Overview
  • 1.3.2 Market Drivers
    • 1.3.2.1 Rapid Technological Advancements in Rare Disease Diagnosis
    • 1.3.2.2 Rising Prevalence of Genetic Disorders and Congenital Disorders
    • 1.3.2.3 Growing Recognition and Emphasis on Early Detection and Prevention of Rare Diseases in Pediatric Populations
  • 1.3.3 Market Challenges
    • 1.3.3.1 Lack of Consolidation of Information Leading to Difficulty in Diagnosis
    • 1.3.3.2 Significant Capital Requirement for Research and Development Hindering Global Expansion Efforts
  • 1.3.4 Market Opportunities
    • 1.3.4.1 Whole Genome Sequencing Putting an End to the Rare Disease Genetic Testing Odysseys
    • 1.3.4.2 AI-Based Diagnostic Tools Diagnosing Rare Diseases by Identifying Potential Diagnoses
    • 1.3.4.3 Transitioning toward Increased Genetics Coverage in Reimbursement Policies

2 Rare Disease Genetic Testing Market (by Region)

• 2.1 Asia-Pacific Rare Disease Genetic Testing Market
  • 2.1.1 Market Dynamics
    • 2.1.1.1 Impact Analysis
  • 2.1.2 Market Size and Forecast
    • 2.1.2.1 Asia-Pacific Rare Disease Genetic Testing Market (by Disease Type)
    • 2.1.2.2 Asia-Pacific Rare Disease Genetic Testing Market (by Technology)
    • 2.1.2.3 Asia-Pacific Rare Disease Genetic Testing Market (by Country)
      • 2.1.2.3.1 Japan
        • 2.1.2.3.1.1 Market Dynamics
        • 2.1.2.3.1.2 Market Size and Forecast
        • 2.1.2.3.1.2.1 Japan Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.1.2.2 Japan Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.2 China
        • 2.1.2.3.2.1 Market Dynamics
        • 2.1.2.3.2.2 Market Size and Forecast
        • 2.1.2.3.2.2.1 China Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.2.2.2 China Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.3 Australia
        • 2.1.2.3.3.1 Market Dynamics
        • 2.1.2.3.3.2 Market Size and Forecast
        • 2.1.2.3.3.2.1 Australia Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.3.2.2 Australia Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.4 South Korea
        • 2.1.2.3.4.1 Market Dynamics
        • 2.1.2.3.4.2 Market Size and Forecast
        • 2.1.2.3.4.2.1 South Korea Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.4.2.2 South Korea Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.5 India
        • 2.1.2.3.5.1 Market Dynamics
        • 2.1.2.3.5.2 Market Size and Forecast
        • 2.1.2.3.5.2.1 India Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.5.2.2 India Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.6 Singapore
        • 2.1.2.3.6.1 Market Dynamics
        • 2.1.2.3.6.2 Market Size and Forecast
        • 2.1.2.3.6.2.1 Singapore Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.6.2.2 Singapore Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.7 Rest-of-Asia-Pacific
        • 2.1.2.3.7.1 Market Dynamics
        • 2.1.2.3.7.2 Market Size and Forecast
        • 2.1.2.3.7.2.1 Rest-of-Asia-Pacific Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.7.2.2 Rest-of-Asia-Pacific Rare Disease Genetic Testing Market (by Technology)

3 Company Profiles

• 3.1 Overview
  • 3.1.1 3billion, Inc.
    • 3.1.1.1 Company Overview
    • 3.1.1.2 Role of 3billion, Inc. in the Rare Disease Genetic Testing Market
    • 3.1.1.3 Recent Developments
    • 3.1.1.4 Analyst Perspective
  • 3.1.2 Konica Minolta (Ambry Genetics, Inc.)
    • 3.1.2.1 Company Overview
    • 3.1.2.2 Role of Konica Minolta (Ambry Genetics, Inc.) in the Rare Disease Genetic Testing Market
    • 3.1.2.3 Financials
    • 3.1.2.4 Recent Developments
    • 3.1.2.5 Analyst Perspective
  • 3.1.3 BGI Group
    • 3.1.3.1 Company Overview
    • 3.1.3.2 Role of BGI Group in the Rare Disease Genetic Testing Market
    • 3.1.3.3 Financials
    • 3.1.3.4 Recent Developments
    • 3.1.3.5 Analyst Perspective
  • 3.1.4 Strand Life Science Pvt Ltd.
    • 3.1.4.1 Company Overview
    • 3.1.4.2 Role of Strand Life Science Pvt Ltd. in the Rare Disease Genetic Testing Market
    • 3.1.4.3 Recent Developments
    • 3.1.4.4 Analyst Perspective

List of Figures

• Figure 1: Prevalence Rare Disease, 2022
• Figure 2: Asia-Pacific Rare Disease Genetic Testing Market, $Billion, 2022-2033
• Figure 3: Rare Disease Genetic Testing Market, Market Dynamics
• Figure 4: Most Frequently Studied Rare Diseases, 2021
• Figure 5: Asia-Pacific Rare Disease Genetic Testing Market Share (by Technology), 2022 and 2033
• Figure 6: Asia-Pacific Rare Disease Genetic Testing Market Share (by Disease Type), 2022 and 2033
• Figure 7: Share of Key Developments and Strategies, January 2019-June 2023
• Figure 8: Rare Disease Genetic Testing Market: Research Methodology
• Figure 9: Primary Research Methodology
• Figure 10: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 11: Top-Down Approach (Segment-Wise Analysis)
• Figure 12: Asia-Pacific Rare Disease Genetic Testing Market Potential, $Billion, 2022-2033
• Figure 13: Rare Disease Genetic Testing Market, Patent Analysis (by Country), January 2018- June 2023
• Figure 14: Rare Disease Genetic Testing Market, Patent Analysis (by Year), January 2018-June 2023
• Figure 15: NIH Funding on Rare Diseases, $Million, 2013-2023
• Figure 16: Rare Disease Genetic Testing Market Dynamics
• Figure 17: Rare Disease Prevalence in India, 2022
• Figure 18: Prevalence of Rare Diseases, 2022
• Figure 19: Most Frequently Studied Rare Diseases, 2021
• Figure 20: Publications Related to the Use of Artificial Intelligence for Rare Disease Diagnosis, 2015-2022
• Figure 21: Rare Disease Genetic Testing Market Share (by Region), 2022-2033
• Figure 22: Asia-Pacific Rare Disease Genetic Testing Market, $Billion, 2022-2033
• Figure 23: Asia-Pacific Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 24: Asia-Pacific Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 25: Asia-Pacific Rare Disease Genetic Testing Market (by Country), % Share, 2022 and 2033
• Figure 26: Japan Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 27: Japan Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 28: Japan Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 29: China Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 30: China Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 31: China Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 32: Australia Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 33: Australia Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 34: Australia Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 35: South Korea Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 36: South Korea Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 37: South Korea Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 38: India Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 39: India Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 40: India Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 41: Singapore Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 42: Singapore Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 43: Singapore Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 44: Rest-of-Asia-Pacific Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 45: Rest-of-Asia-Pacific Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 46: Rest-of-Asia-Pacific Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 47: Rare Disease Genetic Testing Market, Total Number of Key Companies Profiled
• Figure 48: 3billion, Inc: Product Portfolio
• Figure 49: Konica Minolta (Ambry Genetics, Inc.): Product Portfolio
• Figure 50: Konica Minolta (Ambry Genetics, Inc.).: Overall Financials, $Million, 2020-2022
• Figure 51: Konica Minolta (Ambry Genetics, Inc.): Net Revenue (by Segment), $Million, 2020-2022
• Figure 52: Konica Minolta (Ambry Genetics, Inc.): Net Revenue (by Region), $Million, 2020-2022
• Figure 53: Konica Minolta (Ambry Genetics, Inc.): R&D Expenditure, $Million, 2020-2022
• Figure 54: BGI Genomics: Product Portfolio
• Figure 55: BGI Genomics.: Overall Financials, $Million, 2020-2022
• Figure 56: Strand Life Science Pvt Ltd.: Product Portfolio

List of Tables

• Table 1: Key Questions Answered in the Report
• Table 2: Funding for Rare Disease Research
• Table 3: Technological Advancements in the Rare Disease Genetic Testing Ecosystem
• Table 4: Expansion of Medicare Coverage for Rare Disease Genetic Testing Tests (by Companies)
• Table 5: Asia-Pacific Rare Disease Genetic Testing Market, Impact Analysis